Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2008

View Archived Issues

Wetimicin studied in phase I in China as new broad-spectrum antibiotic

New preclinical data demonstrate antidepressant activity of ITI-007

Aradigm initiates clinical trial of Lung Rx's inhaled treprostinil using AERx Essence

Schering-Plough terminates collaboration agreement with Novacea for Asentar

CuraGen advances CR011-vcMMAE into phase II for advanced melanoma

Futura Medical updates progress on development of TPR-100 using DermaSys

Glucose-lowering activity of Merck's novel glucagon receptor antagonist shown in vivo

Pfizer's novel 5-HT1B inverse agonist shows antidepressant activity in vivo

In vivo cognitive enhancement by WAY-101, a novel 5-HT6 antagonist

Novel agents for cardiovascular disorders disclosed in recent patent

New wound-healing agents described in recent Hokkaido University and Shionogi patent

New immunosuppressants reported in recent patent literature

ImClone Systems initiates phase II clinical trial of IMC-A12 in head and neck cancer

Lorus signs exclusive multinational license agreement with Zoticon for Virulizin

FDA grants orphan drug designation to Kamada's aerosolized AAT for bronchiectasis

Immunomedics reports results from phase I/II study of veltuzumab

Barrier Therapeutics reports positive results from phase II study of oral antihistamine Hivenyl

FDA grants fast track designation to Neopharm's NPL-2008 in autism disorder

Recombinant butyrylcholinesterase may play a neuroprotective role in AD

FDA accepts oritavancin NDA for standard review

Potentia completes round of financing to advance POT-4 clinical program in AMD

Abilify granted EU marketing authorization for manic episodes in bipolar I

Amrubicin designated EMEA orphan medicinal product for small cell lung cancer

Alimta approved for histologically based use in non-small cell lung cancer

Sustained release of platinum species seen with NC-6004 in cancer patients

Clinical responses seen with AME-133v in phase I/II study

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026